Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

Christoph Schliemann, Alessandro Palumbo, Kathrin Zuberbühler, Alessandra Villa, Manuela Kaspar, Eveline Trachsel, Wolfram Klapper, Hans Dietrich Menssen, Dario Neri

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

The antibody-mediated delivery of therapeutic agents to sites of angiogenesis is an attractive strategy for anticancer therapy, but is largely unexplored in hematologic malignancies. In the present study, we show that the extra domain B (EDB) of fibronectin, a marker of angiogenesis, is expressed in B-cell non-Hodgkin lym-phoma (NHL) and that the human monoclonal anti-EDB antibody L19 can selectively localize to the lymphoma-associated subendothelial extracellular matrix. In vivo, the preferential accumulation of the antibody at the tumor site was confirmed by quantitative biodistribution analyses with radioiodinated antibody preparations. The fusion protein L19-IL2, which mediates the delivery of interleukin-2 (IL-2) to the neovasculature, displayed a superior antilymphoma activity compared with unconjugated IL-2 in localized and systemic xenograft models of NHL. When coadministered with rituximab, L19-IL2 induced complete remissions of estab-lished localized lymphomas and provided long-lasting protection from disseminated lymphoma. The combined use of rituximab and L19-IL2, which dramatically increases the infiltration of immune effector cells in lymphomas, may deserve clinical investigations, facilitated by the fact that L19-IL2 is currently being studied in phase II clinical trials in patients with solid tumors. (Blood. 2009;113:2275-2283)

Original languageEnglish
Pages (from-to)2275-2283
Number of pages9
JournalBlood
Volume113
Issue number10
DOIs
Publication statusPublished - Mar 5 2009

Fingerprint

B-Cell Lymphoma
Heterografts
Interleukin-2
Cells
Lymphoma
Antibodies
Non-Hodgkin's Lymphoma
Tumors
Neoplasm Antibodies
Phase II Clinical Trials
Hematologic Neoplasms
Fibronectins
Infiltration
Extracellular Matrix
L19-IL2 immunocytokine
Rituximab
Blood
B-Lymphocytes
Fusion reactions
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Schliemann, C., Palumbo, A., Zuberbühler, K., Villa, A., Kaspar, M., Trachsel, E., ... Neri, D. (2009). Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood, 113(10), 2275-2283. https://doi.org/10.1182/blood-2008-05-160747

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. / Schliemann, Christoph; Palumbo, Alessandro; Zuberbühler, Kathrin; Villa, Alessandra; Kaspar, Manuela; Trachsel, Eveline; Klapper, Wolfram; Menssen, Hans Dietrich; Neri, Dario.

In: Blood, Vol. 113, No. 10, 05.03.2009, p. 2275-2283.

Research output: Contribution to journalArticle

Schliemann, C, Palumbo, A, Zuberbühler, K, Villa, A, Kaspar, M, Trachsel, E, Klapper, W, Menssen, HD & Neri, D 2009, 'Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2', Blood, vol. 113, no. 10, pp. 2275-2283. https://doi.org/10.1182/blood-2008-05-160747
Schliemann C, Palumbo A, Zuberbühler K, Villa A, Kaspar M, Trachsel E et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood. 2009 Mar 5;113(10):2275-2283. https://doi.org/10.1182/blood-2008-05-160747
Schliemann, Christoph ; Palumbo, Alessandro ; Zuberbühler, Kathrin ; Villa, Alessandra ; Kaspar, Manuela ; Trachsel, Eveline ; Klapper, Wolfram ; Menssen, Hans Dietrich ; Neri, Dario. / Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. In: Blood. 2009 ; Vol. 113, No. 10. pp. 2275-2283.
@article{993396c0937740b3a326f22be766f699,
title = "Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2",
abstract = "The antibody-mediated delivery of therapeutic agents to sites of angiogenesis is an attractive strategy for anticancer therapy, but is largely unexplored in hematologic malignancies. In the present study, we show that the extra domain B (EDB) of fibronectin, a marker of angiogenesis, is expressed in B-cell non-Hodgkin lym-phoma (NHL) and that the human monoclonal anti-EDB antibody L19 can selectively localize to the lymphoma-associated subendothelial extracellular matrix. In vivo, the preferential accumulation of the antibody at the tumor site was confirmed by quantitative biodistribution analyses with radioiodinated antibody preparations. The fusion protein L19-IL2, which mediates the delivery of interleukin-2 (IL-2) to the neovasculature, displayed a superior antilymphoma activity compared with unconjugated IL-2 in localized and systemic xenograft models of NHL. When coadministered with rituximab, L19-IL2 induced complete remissions of estab-lished localized lymphomas and provided long-lasting protection from disseminated lymphoma. The combined use of rituximab and L19-IL2, which dramatically increases the infiltration of immune effector cells in lymphomas, may deserve clinical investigations, facilitated by the fact that L19-IL2 is currently being studied in phase II clinical trials in patients with solid tumors. (Blood. 2009;113:2275-2283)",
author = "Christoph Schliemann and Alessandro Palumbo and Kathrin Zuberb{\"u}hler and Alessandra Villa and Manuela Kaspar and Eveline Trachsel and Wolfram Klapper and Menssen, {Hans Dietrich} and Dario Neri",
year = "2009",
month = "3",
day = "5",
doi = "10.1182/blood-2008-05-160747",
language = "English",
volume = "113",
pages = "2275--2283",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

AU - Schliemann, Christoph

AU - Palumbo, Alessandro

AU - Zuberbühler, Kathrin

AU - Villa, Alessandra

AU - Kaspar, Manuela

AU - Trachsel, Eveline

AU - Klapper, Wolfram

AU - Menssen, Hans Dietrich

AU - Neri, Dario

PY - 2009/3/5

Y1 - 2009/3/5

N2 - The antibody-mediated delivery of therapeutic agents to sites of angiogenesis is an attractive strategy for anticancer therapy, but is largely unexplored in hematologic malignancies. In the present study, we show that the extra domain B (EDB) of fibronectin, a marker of angiogenesis, is expressed in B-cell non-Hodgkin lym-phoma (NHL) and that the human monoclonal anti-EDB antibody L19 can selectively localize to the lymphoma-associated subendothelial extracellular matrix. In vivo, the preferential accumulation of the antibody at the tumor site was confirmed by quantitative biodistribution analyses with radioiodinated antibody preparations. The fusion protein L19-IL2, which mediates the delivery of interleukin-2 (IL-2) to the neovasculature, displayed a superior antilymphoma activity compared with unconjugated IL-2 in localized and systemic xenograft models of NHL. When coadministered with rituximab, L19-IL2 induced complete remissions of estab-lished localized lymphomas and provided long-lasting protection from disseminated lymphoma. The combined use of rituximab and L19-IL2, which dramatically increases the infiltration of immune effector cells in lymphomas, may deserve clinical investigations, facilitated by the fact that L19-IL2 is currently being studied in phase II clinical trials in patients with solid tumors. (Blood. 2009;113:2275-2283)

AB - The antibody-mediated delivery of therapeutic agents to sites of angiogenesis is an attractive strategy for anticancer therapy, but is largely unexplored in hematologic malignancies. In the present study, we show that the extra domain B (EDB) of fibronectin, a marker of angiogenesis, is expressed in B-cell non-Hodgkin lym-phoma (NHL) and that the human monoclonal anti-EDB antibody L19 can selectively localize to the lymphoma-associated subendothelial extracellular matrix. In vivo, the preferential accumulation of the antibody at the tumor site was confirmed by quantitative biodistribution analyses with radioiodinated antibody preparations. The fusion protein L19-IL2, which mediates the delivery of interleukin-2 (IL-2) to the neovasculature, displayed a superior antilymphoma activity compared with unconjugated IL-2 in localized and systemic xenograft models of NHL. When coadministered with rituximab, L19-IL2 induced complete remissions of estab-lished localized lymphomas and provided long-lasting protection from disseminated lymphoma. The combined use of rituximab and L19-IL2, which dramatically increases the infiltration of immune effector cells in lymphomas, may deserve clinical investigations, facilitated by the fact that L19-IL2 is currently being studied in phase II clinical trials in patients with solid tumors. (Blood. 2009;113:2275-2283)

UR - http://www.scopus.com/inward/record.url?scp=63849274108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849274108&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-05-160747

DO - 10.1182/blood-2008-05-160747

M3 - Article

C2 - 19005180

AN - SCOPUS:63849274108

VL - 113

SP - 2275

EP - 2283

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -